The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions

K Dheda, T Perumal, H Moultrie, R Perumal… - The Lancet …, 2022 - thelancet.com
The global tuberculosis burden remains substantial, with more than 10 million people newly
ill per year. Nevertheless, tuberculosis incidence has slowly declined over the past decade …

Tuberculosis drug discovery: challenges and new horizons

GFS Fernandes, AM Thompson… - Journal of Medicinal …, 2022 - ACS Publications
Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …

Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection

PK Drain, KL Bajema, D Dowdy, K Dheda… - Clinical microbiology …, 2018 - Am Soc Microbiol
Tuberculosis (TB) is the leading infectious cause of mortality worldwide, due in part to a
limited understanding of its clinical pathogenic spectrum of infection and disease …

Immunology of Mycobacterium tuberculosis Infections

JK Sia, J Rengarajan - Microbiology spectrum, 2019 - Am Soc Microbiol
Tuberculosis (TB) is a serious global public health challenge that results in significant
morbidity and mortality worldwide. TB is caused by infection with the bacilli Mycobacterium …

Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment

A Allué-Guardia, JI García, JB Torrelles - Frontiers in Microbiology, 2021 - frontiersin.org
In the last two decades, multi (MDR), extensively (XDR), extremely (XXDR) and total (TDR)
drug-resistant Mycobacterium tuberculosis (M. tb) strains have emerged as a threat to public …

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis

O Van Der Meeren, M Hatherill, V Nduba… - … England Journal of …, 2018 - Mass Medical Soc
Background A vaccine to interrupt the transmission of tuberculosis is needed. Methods We
conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01E …

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

S Tiberi, N du Plessis, G Walzl, MJ Vjecha… - The Lancet Infectious …, 2018 - thelancet.com
Tuberculosis remains the world's leading cause of death from an infectious disease,
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …

A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis

P Miotto, B Tessema, E Tagliani… - European …, 2017 - Eur Respiratory Soc
A clear understanding of the genetic basis of antibiotic resistance in Mycobacterium
tuberculosis is required to accelerate the development of rapid drug susceptibility testing …

Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care

N Dookie, S Rambaran, N Padayatchi… - Journal of …, 2018 - academic.oup.com
Abstract Drug-resistant TB (DR-TB) remains a significant challenge in TB treatment and
control programmes worldwide. Advances in sequencing technology have significantly …

Drug‐resistant tuberculosis: an update on disease burden, diagnosis and treatment

C Lange, D Chesov, J Heyckendorf, CC Leung… - …, 2018 - Wiley Online Library
The emergence of antimicrobial resistance against Mycobacterium tuberculosis, the leading
cause of mortality due to a single microbial pathogen worldwide, represents a growing threat …